Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
about
Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiaeCharacterization of the RNA binding energetics of the Candida albicans poly(A) polymerase.Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.Masking of β(1-3)-glucan in the cell wall of Candida albicans from detection by innate immune cells depends on phosphatidylserine.Antifungal and cytotoxicity activities of the fresh xylem sap of Hymenaea courbaril L. and its major constituent fisetin.Fungal cell wall septation and cytokinesis are inhibited by bleomycinsSimilar efficacy of broad-range ITS PCR and conventional fungal culture for diagnosing fungal infections in non-immunocompromised patients.Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.Gene Expression and Identification Related to Fluconazole Resistance of Candida glabrata Strains.Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.Candida albicans-macrophage interactions: genomic and proteomic insights.Developing genetic tools to exploit Chaetomium thermophilum for biochemical analyses of eukaryotic macromolecular assembliesExpression Patterns of ABC Transporter Genes in Fluconazole-Resistant Candida glabrata.Synergic effect of combination of glycyrol and fluconazole against experimental cutaneous candidiasis due to Candida albicans.Mechanisms of azole resistance in a clinical isolate of Candida tropicalis.Antifungal resistance and new strategies to control fungal infections.Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction.Mutants with heteroresistance to amphotericin B and fluconazole in Candida.Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine.In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis.Diagnostic value of signs and symptoms of mammary candidosis among lactating women.Role of three Cryptococcus neoformans and C. gattii efflux pump coding genes in response to drug treatment.
P2860
Q27939054-2624CB81-B82F-4DE5-8805-B3DE3DB5E9C7Q30360889-731942E7-2F23-487D-9370-FCD7E9D7C683Q33940714-8B318CF1-8766-4171-8456-9111107167EDQ34298661-FB8859D7-21B8-456E-84D3-30DDE2AA9F65Q35207247-88720B63-200B-4F2D-ABE6-FBA00CA3A60BQ36047788-B4BCAEEB-542B-4DCE-B382-EB713303FB42Q36062751-27D746F2-F688-4409-913C-A7FF5AC3752BQ36077230-3B64CBAF-2DD1-4994-8580-961408E5A2F6Q37155657-569F67F9-17B9-4F19-AFAF-67109669B91DQ37247798-0648AA87-97FC-4C3A-A4C1-50EF10FF2904Q37345802-D062B48A-4C94-4E04-B853-ECA780D8B868Q38364764-6CC84994-36A1-4060-A1CE-C52E5B61804BQ39026296-449FBDE2-A896-4013-B9E5-91F847939FEAQ39443256-A8A36D70-701F-4789-9C2F-955B773D50F7Q39610249-05400C07-C382-49E5-91AB-CED445666900Q39751373-8861DF26-6975-4473-8F2D-6BFBAD4164FCQ40197295-F51939F2-E27E-46CC-A77A-9C7173B7250EQ42156902-A32F4453-242C-44EA-B8FE-99969D58A59FQ42408739-C06B53AB-6BDB-4587-B02C-662077891ECAQ43152151-EEE18B37-7EA3-4AAD-B372-0244B5E06F9EQ43646246-9ACAAFEB-4A24-4E5C-B562-418F4172AE4CQ46697354-62C158FF-9EF3-49B0-BD3E-4018AAD9DE90Q49598890-4E78F1ED-CC20-4F13-99D9-27590F205CFA
P2860
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@ast
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@en
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@nl
type
label
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@ast
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@en
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@nl
prefLabel
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@ast
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@en
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@nl
P1476
Clinical relevance of mechanisms of antifungal drug resistance in yeasts.
@en
P2093
Dominique Sanglard
P304
462-9; quiz 470, 479
P356
10.1016/S0213-005X(02)72842-5
P577
2002-11-01T00:00:00Z